Novo Nordisk Research and Development UK Limited
Registered name: NOVO NORDISK RESEARCH AND DEVELOPMENT UK LIMITED
Part of Novo Nordisk A/S groupNovo Nordisk Research and Development UK Limited made £52.2m revenue and £2.5m profit in the year to 31 Dec 2025.
Novo Nordisk Research and Development UK Limited’s revenue grew 37% to £52.2m in the year to 31 Dec 2025, with £2.5m profit and 181 employees. The company is classified under “research and experimental development on biotechnology” and is based in Oxford; we hold 3 years of its filed accounts.
- Status
- Active
- Location
- Oxford, South East
- Age
- 12 yrs · since 2014
- Type
- Private Limited Company
Part of a group. The filing indicates this company sits within a group structure, so its results may depend on intra-group trading and it may be hard to replicate independently.
Key figures
Badges are automated estimates derived from the filed figures — not statements of fact about the company.
Financial history
| Year to | 31 Dec 2023 | 31 Dec 2024 | 31 Dec 2025 |
|---|---|---|---|
| Disclosure | Full P&L | Full P&L | Full P&L |
| Profit & loss | |||
| Revenue (turnover) | £28.3m | £38m | £52.2m |
| Operating profit | £2.4m | £3.3m | £5.7m |
| Profit before tax | £2.4m | £3.3m | £4m |
| Profit after tax | £1.7m | £1.9m | £2.5m |
| Profit (best available) | £1.7m | £1.9m | £2.5m |
| Employees (average) | — | 150 | 181 |
| Ratios | |||
| Profit margin | 6% | 4.9% | 4.7% |
| Revenue per employee | — | £254k | £289k |
| Profit per employee | — | £12.5k | £13.6k |
| Growth (year on year) | |||
| Revenue growth | — | ▲34.2% | ▲37.3% |
| Profit growth | — | ▲11.1% | ▲31.3% |
| Headcount growth | — | — | ▲20.7% |
| Balance sheet — indirect signals, not revenue | |||
| Net assets | — | — | — |
| Source | Accounts · bulk data Jun 2025 | Accounts · bulk data Jun 2025 | Accounts · bulk data Sep 2026 |
How the business works
- Profit margin
- 4.7%
- Profit ÷ revenue.
- Gross margin
- —
- Gross profit ÷ revenue. High for software and services.
- Revenue per employee
- £289k
- Revenue ÷ average employees.
- Profit per employee
- £13.6k
- Profit ÷ average employees.
- Cash conversion
- —
- Cash generated from operations ÷ operating profit. Needs a cash-flow statement.
- Fixed assets ÷ revenue
- —
- Capital intensity. Low = capital-light, cheaper to start.
- Deferred income ÷ revenue
- —
- Customers paying upfront (subscriptions, deposits). Approximate when combined with accruals.
- Debtors ÷ revenue
- —
- Money owed by customers. Low = customers pay quickly.
Balance-sheet signals
Year-on-year changes in filed balance-sheet items. They can hint at momentum (or investment) but are not revenue or profit and must not be read as such.
- Net assets
- —
- Now —
- Cash at bank
- —
- Now —
- Headcount
- ▲21%
- Now 181
- Deferred income
- —
- Now —
- Fixed assets
- —
- Now —
Group structure
Ownership chain
- Novo Nordisk A/S (registered outside the UK register)ultimate parent75–100%
- Novo Nordisk Research and Development UK Limitedthis company
Bands show the share of ownership each company holds in the one below it.
From the Persons with Significant Control register (corporate controllers only).
Similar profitable businesses
- Qiagen Manchester LimitedManchester · Research and experimental development on biotechnology
- Revenue
- £53.7m
- Profit
- £11.8m
- Staff
- 239
- Novogene (UK) Company LimitedCambridge · Research and experimental development on biotechnology
- Revenue
- £38.2m
- Profit
- £2.8m
- Staff
- 68
- Amphista Therapeutics LimitedCambridge · Research and experimental development on biotechnology
- Revenue
- £33.9m
- Profit
- £19.8m
- Staff
- 56
- Alchemab Therapeutics LtdLondon · Research and experimental development on biotechnology
- Revenue
- £30m
- Profit
- £8.3m
- Staff
- 55
- Sitryx Therapeutics LimitedOxford · Research and experimental development on biotechnology
- Revenue
- £23.3m
- Profit
- £4.7m
- Staff
- —
- Charles River U.K. LimitedKent · Research and experimental development on biotechnology
- Revenue
- £22.2m
- Profit
- £18.8m
- Staff
- 129
Sources
Latest figures from accounts for the year to 31 Dec 2025 (profit £2.5m), from the Companies House accounts bulk data published Sep 2026. Spotted an error? Request a correction.
Updated from Companies House on 12 Oct 2026
Contains public sector information from Companies House licensed under the Open Government Licence v3.0. Data from Companies House, © Crown copyright. View the licence.